FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023911946> ?p ?o ?g. }

• W2023911946 endingPage "246" @default.
• W2023911946 startingPage "244" @default.
• W2023911946 abstract "A clinically significant drug response rarely achieves adequate disease control, resulting in the need for combination pharmacotherapy. Virtually every prevalent chronic condition including hypertension, coronary artery disease, hyperlipidemia, chronic obstructive pulmonary disease, rheumatoid arthritis, and diabetes are commonly treated with combination drug regimens. Non-neurogenic male lower urinary tract symptoms (NNMLUTS) should be no exception. a-Blockers, 5a-reductase inhibitors (5-ARIs), antimuscarinics (anti-Ms), and phosphodiesterase (PDE) inhibitors are effective monotherapies for subsets of NNMLUTS. These monotherapies rarely ‘‘cure’’ LUTS. Therefore, combining these agents is the next obvious step in pharmacologic management of NNMLUTS. Fullhase et al. [1] examined the medical evidence supporting combination medical treatment of NNMLUTS. The authors are to be congratulated for their comprehensive and scholarly systematic review. Unfortunately, there are at least three fundamental limitations of the medical literature for NNMLUTS combination therapy. First, there is a paucity of randomized, double-blind, placebo-controlled trials for themajority of the combinations. Second, there are no cost-effectiveness studies to assess whether observed benefits justify the added cost. Third, the definition of NNMLUTS is unclear. The differential diagnosis of NNMLUTS includes a multitude of non-neurogenic factors that contribute to lower urinary tract symptoms (LUTS). For several of the a-blocker/5-ARI studies identified in the review, NNMLUTS includes clinical benign prostatic hyperplasia (BPH). For other a-blocker/5-ARI studies, NNMLUTS includes clinical BPH and large prostates. For most a-blocker/anti-M studies, NNMLUTS includes clinical BPH refractory to a-blockers. For the a-blocker/PDE studies, NNMLUTS includes BPH and erectile dysfunction. Every combination examined by Fullhase et al. defines a unique cohort of men with NNMLUTS. I have been an active participant in the evolving story of medical therapy since 1983, when I characterized the human prostatic a1 adrenoceptors. I will use this editorial as an opportunity to express my perspective about the role of combination medical therapy for BPH (NNMLUTS) based onmy interpretation of themedical evidence with, at times, deviation from the conclusions of Fullhase et al. [1]. I will limit my comments to the a-blocker plus 5-ARI and a-blocker plus anti-M combinations because the medical evidence for all other combinations is deficient. I will also limit my analysis to LUTS and disease progression due to space limitations." @default.
• W2023911946 created "2016-06-24" @default.
• W2023911946 creator A5011556876 @default.
• W2023911946 date "2013-08-01" @default.
• W2023911946 modified "2023-10-10" @default.
• W2023911946 title "Combination Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms: 1 + 1 Does Not Equal 2" @default.
• W2023911946 cites W2142727765 @default.
• W2023911946 doi "https://doi.org/10.1016/j.eururo.2013.02.021" @default.
• W2023911946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23473577" @default.
• W2023911946 hasPublicationYear "2013" @default.
• W2023911946 type Work @default.
• W2023911946 sameAs 2023911946 @default.
• W2023911946 citedByCount "2" @default.
• W2023911946 countsByYear W20239119462013 @default.
• W2023911946 crossrefType "journal-article" @default.
• W2023911946 hasAuthorship W2023911946A5011556876 @default.
• W2023911946 hasConcept C121608353 @default.
• W2023911946 hasConcept C126322002 @default.
• W2023911946 hasConcept C126894567 @default.
• W2023911946 hasConcept C2776235491 @default.
• W2023911946 hasConcept C2779478474 @default.
• W2023911946 hasConcept C71924100 @default.
• W2023911946 hasConcept C77411442 @default.
• W2023911946 hasConceptScore W2023911946C121608353 @default.
• W2023911946 hasConceptScore W2023911946C126322002 @default.
• W2023911946 hasConceptScore W2023911946C126894567 @default.
• W2023911946 hasConceptScore W2023911946C2776235491 @default.
• W2023911946 hasConceptScore W2023911946C2779478474 @default.
• W2023911946 hasConceptScore W2023911946C71924100 @default.
• W2023911946 hasConceptScore W2023911946C77411442 @default.
• W2023911946 hasIssue "2" @default.
• W2023911946 hasLocation W20239119461 @default.
• W2023911946 hasLocation W20239119462 @default.
• W2023911946 hasOpenAccess W2023911946 @default.
• W2023911946 hasPrimaryLocation W20239119461 @default.
• W2023911946 hasRelatedWork W2100669542 @default.
• W2023911946 hasRelatedWork W2102736746 @default.
• W2023911946 hasRelatedWork W2141781475 @default.
• W2023911946 hasRelatedWork W2143580412 @default.
• W2023911946 hasRelatedWork W2315120746 @default.
• W2023911946 hasRelatedWork W2316319932 @default.
• W2023911946 hasRelatedWork W2348308352 @default.
• W2023911946 hasRelatedWork W2465371616 @default.
• W2023911946 hasRelatedWork W2769152137 @default.
• W2023911946 hasRelatedWork W2790115337 @default.
• W2023911946 hasVolume "64" @default.
• W2023911946 isParatext "false" @default.
• W2023911946 isRetracted "false" @default.
• W2023911946 magId "2023911946" @default.
• W2023911946 workType "article" @default.